H.C. Wainwright Downgrades ZIOPHARM Oncology (ZIOP) to Neutral
- Global stocks eye new high on growth hopes, oil ebbs on COVID-19 fears
- Oil extends losses on U.S. stock build, pandemic concerns
- Cathie Wood's ARK Buys Over 5M Shares of Skillz (SKLZ), Nearly 3M Shares of IPO UiPath (PATH)
- Chipotle Mexican Grill (CMG) Tops Q1 Profit Views, Analysts Maintain Bullishness For 2021
H.C. Wainwright analyst Swayampakula Ramakanth downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from Buy to Neutral.
Shares of ZIOPHARM Oncology closed at $5.33 yesterday.
You May Also Be Interested In
- Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell
- Goldman Sachs Downgrades Mercialys (MERY:FP) (MEYIF) to Neutral
- Facebook (FB) PT Raised to $360 at Jefferies Into Q1 EPS, Sees Estimates as 'Too Conservative'